The result of IFNG promoter methylation of CpG sites demonstrated hypermethylation was similar to that observed in CD4+ T cells of lung cancer patients (85.4% vs 85.4%), which generated lower levels of IFNG upon activation. The gene discussed is CD4; the disease is lung cancer.